TY - JOUR
T1 - Fibroblast growth factor receptor 1 (FGFR1) copy number is an independent prognostic factor in non-small cell lung cancer
AU - Tran, Thang N.
AU - Selinger, Christina I.
AU - Kohonen-Corish, Maija R. J.
AU - McCaughan, Brian C.
AU - Kennedy, Catherine W.
AU - O'Toole, Sandra A.
AU - Cooper, Wendy A.
PY - 2013
Y1 - 2013
N2 - Fibroblast growth factor receptor 1 ( FGFR1) is an oncogene that can potentially be targeted by tyrosine kinase inhibitors. We aimed to investigate the prevalence and prognostic significance of alterations in FGFR1 copy number in non-small cell lung cancer (NSCLC). FGFR1 status was evaluated by chromogenic silver in situ hybridisation (ISH) in tissue microarray sections from a retrospective cohort of 304 surgically resected NSCLCs and results were correlated with the clinicopathological features and overall survival. High FGFR1 gene copy number (amplification or high-level polysomy) was significantly more frequent in squamous cell carcinomas (SCC) (24.8%) and large cell carcinomas (LCC) (25%) compared to adenocarcinomas (11.3%) ( p= 0.01 and p= 0.03 respectively). Among NSCLC there was no significant correlation between FGFR1-positive status and other clinicopathological features including age, gender, smoking history, tumour size, lymph node status, stage, grade, vascular, lymphatic or perineural invasion. FGFR1-positive patients showed a tendency to longer overall survival in univariate analysis ( p= 0.14). Multivariate survival analysis using Cox regression model confirmed FGFR1-positive patients had a significant reduction in the risk of death compared to FGFR1-negative patients (HR 0.6; p= 0.02). High. FGFR1 gene copy number is a common finding in SCC and LCC and is an independent favourable prognostic factor.
AB - Fibroblast growth factor receptor 1 ( FGFR1) is an oncogene that can potentially be targeted by tyrosine kinase inhibitors. We aimed to investigate the prevalence and prognostic significance of alterations in FGFR1 copy number in non-small cell lung cancer (NSCLC). FGFR1 status was evaluated by chromogenic silver in situ hybridisation (ISH) in tissue microarray sections from a retrospective cohort of 304 surgically resected NSCLCs and results were correlated with the clinicopathological features and overall survival. High FGFR1 gene copy number (amplification or high-level polysomy) was significantly more frequent in squamous cell carcinomas (SCC) (24.8%) and large cell carcinomas (LCC) (25%) compared to adenocarcinomas (11.3%) ( p= 0.01 and p= 0.03 respectively). Among NSCLC there was no significant correlation between FGFR1-positive status and other clinicopathological features including age, gender, smoking history, tumour size, lymph node status, stage, grade, vascular, lymphatic or perineural invasion. FGFR1-positive patients showed a tendency to longer overall survival in univariate analysis ( p= 0.14). Multivariate survival analysis using Cox regression model confirmed FGFR1-positive patients had a significant reduction in the risk of death compared to FGFR1-negative patients (HR 0.6; p= 0.02). High. FGFR1 gene copy number is a common finding in SCC and LCC and is an independent favourable prognostic factor.
UR - http://handle.uws.edu.au:8081/1959.7/533776
U2 - 10.1016/j.lungcan.2013.05.015
DO - 10.1016/j.lungcan.2013.05.015
M3 - Article
SN - 0169-5002
VL - 81
SP - 462
EP - 467
JO - Lung Cancer
JF - Lung Cancer
IS - 3
ER -
